OneCell Diagnostics, a Cupertino, CA- and Mumbai, India-based genomics-based precision oncology firm, raised $16M in Sequence A Funding.
The spherical was led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. Celesta Capital Founding Managing Accomplice Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will be part of the OneCell board of administrators.
The corporate intends to make use of the funds to broaden to the U.S. market with its next-generation liquid biopsy take a look at, OncoIndx Ikon.
Led by CEO Mohan Uttarwar, OneCell Diagnostics is a genomics-based precision oncology firm, offering complete genomic options for higher most cancers administration. Its proprietary know-how leverages a mixture of sequencing together with bioinformatics, AI / ML, and data-analytics for multi-omics biomarkers. Their most cancers screening checks are based mostly on a proprietary Circulating Tumor Cell (CTC) and True-Single-Cell-Multi-omics platform, supporting a variety of purposes in scientific most cancers care and early-stage scientific trials for biotech and pharma corporations. OneCell’s cell biopsy know-how integrates CTC-DNA with CTC-RNA and cell floor protein testing, all from a single blood draw, a big development over present “liquid biopsy” testing.
Its operations are headquartered in Silicon Valley and India.
FinSMEs
22/11/2024
